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Abstract
Backgroud: Gluteal muscle contracture (GMC) is a multi-factor human chronic fibrotic disease of the gluteal
muscle. Fibrotic tissue is characterized by excessive accumulation of collagen in the muscle’s extracellular matrix.
Transforming growth factor (TGF)-b1 and -b2 are thought to play an important role in fibrogenesis, while TGF-b3i s
believed to have an anti-fibrotic function. We hypothesize that the expression of collagen and TGF-bs would be
up-regulated in GMC patients.
Methods: The expression of collagen type I, type III and TGF-bs were studied in 23 fibrotic samples and 23
normal/control samples in GMC patients using immunohistochemistry, reverse transcription and polymerase chain
reaction (RT-PCR) and western bolt analysis.
Results: Compared to the unaffected adjacent muscle, increased expression of TGF-b1 and -b3 was associated
with deposition of collagen type I and type III in the fibrotic muscle of the GMC patients at the mRNA level. Strong
up-regulation of these proteins in fibrotic muscle was confirmed by immunohistochemical staining and western
blot analysis. TGF-b2 was not up-regulated in relation to GMC.
Conclusion: This study confirmed our hypothesis that collagen types I, III, TGF-b1 and TGF-b3 were up-regulated in
biopsy specimens obtained from patients with GMC. Complex interaction of TGF-b1 with profibrotic function and
TGF-b3 with antifibrotic function may increase synthesis of collagens and thereby significantly contribute to the
process of gluteal muscle scarring in patients with GMC.
Background
Gluteal muscle contracture (GMC) is a clinical syn-
drome with multiple etiologies, either congenital or
acquired, GMC is not uncommon and exists worldwide
[1-5]. Clinically, GMC progresses through distinct
stages. The earliest stage is characterized by unnoticed
difficulties in adducting the hip or squatting, and over
time, it gives rise to serious functional disorders of the
hip. Although abnormal scarring is a known phenom-
enon in the fibrotic muscle (contraction band) of GMC
patients, the mechanism of this human chronic fibrotic
muscle disorder is not known.
Transforming growth factor (TGF)-bsa r em e m b e r so f
a superfamily of polypeptides which play a key role in
cell regulation, angiogenesis, embryo development,
apoptosis induction, and wound healing [6-8]. Three
isoforms of TGF-b are known to exist in mammals,
namely TGF-b1, -b2, and -b3, each with distinct roles in
wound repair. TGF-b1a n d- b2 are potent profibrotic
factors thought to be involved in the pathogenesis of
many fibrotic diseases and are important in almost
every step in the process of tissue fibrosis by simulta-
neously signaling fibroblasts to increase the synthesis of
matrix proteins, decrease the production of matrix-
degrading proteases, and increase the production of
inhibitors of these proteases [9,10]. Both in vitro and in
vivo studies have revealed an over-expression of TGF-b1
and TGF-b2 in fibrotic lesions, and convincingly
demonstrated that blocking the bioactivity of TGF-b1
and -b2 could suppress collagen production and subse-
quently could modulate the fibrotic process [11,12]. In
contrast, TGF-b3 reduces the fibrotic response. The
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ring properties as well [13,14].
Although fibrogenic roles for each of the three iso-
forms of TGF-bs have been documented during fibrosis
in various tissues and organs, their roles in GMC
patients are not known. This study was designed, there-
fore, with an expectation of finding an increased expres-
sion of collagen types I and III, and TGF-bsi nt h i s
fibrotic disease of gluteal muscle.
Methods
Tissue specimens and antibodies
Between January 2007 and March 2008, 46 samples (23
contraction bands and 23 adjacent normal muscle sam-
ples) of GMC patients were enrolled in this study in the
Department of Orthopaedic Surgery of The 2nd
Affiliated Hospital of Medical College of Xi’an JiaoTong
University. All our studies were permitted by the Ethical
Board of The 2nd Affiliated Hospital of Medical College
of Xi’an JiaoTong University and followed the Declara-
tion of Helsinki Guidelines. Informed consent was
obtained from all of the patients. All 23 patients (10
males and 13 females between the ages of 7 to 27 years,
8 years of course at least) were carried out with contrac-
tion band releasing surgery as we described before [1].
Tissues used for RT-PCR and western blot analysis were
immediately frozen in liquid nitrogen and stocked at
-80°C. Mouse anti-human monoclonal antibodies against
collagen types I and III were purchased from Abcam
(Cambridge, UK), and mouse anti-human monoclonal
antibodies against TGF-b1, -b2, and b-3 were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA,
US). Second antibody for immunohistochemical analyses
(biotinylated goat anti-mouse IgG antibody) was
obtained from Vector Laboratories (Burlingame, CA,
USA).
Histology and immunohistochemistry
Tissue samples were fixed in 4% paraformaldehyde at 4°
C for 24 hours. Paraffin sections (4 um) for histologic
analysis were stained with hematoxylin/eosin, Masson
trichrome, and picrosirius. For immunohistochemical
analysis, paraffin sections were deparaffinized with
xylene, rinsed thoroughly with ethanol, then soaked in
0.3% hydrogen peroxide in methanol to inactivate endo-
genous peroxidase activity. After mild treatment with
0.05% trypsin-EDTA, the sections were incubated with
10% goat serum to block non-specific protein binding.
The blocked sections were incubated with antibodies
against collagen types I and III (1:800), or antibodies
against TGF-b1, -b2, and -b3 (1:200) at 4°C overnight.
After incubation with the primary antibody, the sections
were incubated with second antibody and alkaline phos-
phatase streptavidin (Vector Laboratories, Burlingame,
CA, USA). The sections were stained using a Vector
Red Alkaline Phosphatase Substrate Kit (Vector Labora-
tories) according to the manufacturer’si n s t r u c t i o n sa n d
counterstained with Mayer’s hematoxylin. One section
from each series was incubated with PBS as the first
antibody as a negative control. The staining intensities
of collagen types I and III, TGF-b1, -b2, and -b3i nt h e
contraction band and unaffected adjacent muscle were
graded semi-quantitatively using the following scale: (-)
= no staining; (+) = weak staining; (++) = moderate
staining; and (+++) = strong staining.
Reverse transcription and polymerase chain reaction (RT-
PCR)
Total RNA was extracted from samples using Trizol
reagent (Invitrogen Corp., Carlsbad, CA, USA) accord-
ing to the manufacturer’s protocol. Five micrograms of
total RNA template were used to make cDNA by using
a RevertAid First Strand cDNA Synthesis Kit (Fermen-
tas, Vilnius, Lithuania), using random hexamers as the
first-strand primer. A polymerase chain reaction (PCR)
was performed using TaKaRa Ex Taq HS (TaKaRa, Da
Lian, China) and the synthetic gene-specific primers for
collagen types I and III, TGF-b1, -b2, -b3, and b-actin
used in the RT-PCR are listed in Table 1. All target
sequences were separately amplified for 35 cycles. Sam-
ples of each reaction product were separated by agarose
gel electrophoresis, visualized by ethidium bromide
staining, and photographed with 290-nm ultraviolet illu-
mination. The density of each band was measured by
densitometry. Relative expression of collagen types I III,
TGF-b1, -b2, and -b3 mRNA were normalized to the
expression of the internal control (b-actin).
Western blot analysis
Tissue protein extracts were prepared using a modified
RIPA buffer (50 mM Tris-HCl [pH 7.4], 1% NP-40, 150
mM NaCl, and 1 mM EDTA) supplemented with a
cocktail of protease inhibitors (1 mM PMSF [1 μg/mL
of aprotinin, leupeptin, and pepstatin]). Tissue was
homogenized at 4°C and the resulting homogenate cen-
trifuged for 12,000 rpm for 15 min at 4°C to remove
cell debris. Sample protein concentrations were quanti-
fied using the BCA protein assay (Pierce, Rockford, IL,
USA). Equivalent levels of protein (20 μg) were analyzed
by SDS-PAGE and subsequently transferred to polyviny-
lidene difuoride (PVDF) membranes (Bio-Rad, Hercules,
CA, USA). The membranes were than blocked with 10%
fat-free skim milk powder in phosphate-buffered saline
containing 0.1% Tween 20, and incubated with antibo-
dies against TGF-b1, -b2, and TGF-b3 (1:400). After a
series of brief PBST washes, the membranes were then
incubated with the appropriate species-specific horserad-
ish peroxidase-conjugated antibodies (1:5000; Jackson
ImmunoResearch, West Grove, PA, USA). Antibody-
specific bands were visualized using standard ECL che-
miluminescence reagents (Pierce) and photographed.
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try. The relative expression of collagen types I and III,
TGF-b1, -b2, and-b3 protein were normalized to the
expression of the internal control (b-actin).
Statistical analyses
Densitometric measurement was performed using a GS-
700 Imaging Densitometer with Multi-Analyst software
(Bio-Rad). All values were expressed as the means ± SD.
The paired T-test was used to examine differences
between paired samples. Statistical analysis was per-
formed using SPSS 13.0 software and P values < 0.05
were considered significant.
Results
Histology analysis
Histologic examination was performed on sections
stained with hematoxylin/eosin (Fig. 1A), Masson tri-
chrome (Fig. 1B), or picrosirius (Fig. 1c). We observed
typical fibrotic changes in the contraction band. Irregu-
lar broad segments of collagen fibers accumulated in a
whirl-like pattern and replaced the original skeletal mus-
cle fibers. A small amount of collagen was also observed
within the muscle bundles. We showed that on sections
stained with picrosirius, under polarized microscopy,
collagen types I and III co-existed, and the staining of
type I was more intense (Fig. 1D).
Expression of collagen types I and III is up-regulated in
the contraction band
The mRNA levels of collagen types I and III were deter-
mined using RT-PCR. Compared with adjacent muscle,
the mRNA levels of collagen types I and III were ele-
vated (Fig. 2A; 5 representative cases are shown). Semi-
quantitative densitometric analysis of the blots indicated
that the levels of collagen types I and III mRNA in the
contraction band were increased 5.0- and 8.1-fold,
respectively (Fig. 2B; mean of 23 cases; P < 0.01), rela-
tive to unaffected adjacent muscle in the same patients.
To further explore whether the up-regulation of mRNA
levels for collagen types I and III leads to increased pro-
tein levels, an immunohistochemical analysis was per-
formed to detect collagen types I and III (Fig.1E-1H).
Collagen types I and III were weakly present in the adja-
cent muscle (+). Compared to unaffected adjacent mus-
cle, expression of collagen types I (+++) and III (++)
was detected in the contraction band, which is consis-
tent with findings from sections stained with picrosirius
(Table 2). All of these indicate an increased expression
of collagen types I and III in GMC.
Expression of TGF-b1 and -b3 mRNA is up-regulated in
the contraction band
As TGF-b1, -b2, and -b3 have a close relationship with
the process of tissue fibrosis, we first examined the
mRNA level in the contraction band by RT-PCR. The
expression of TGF-b1a n d- b3 was weakly detected in
unaffected adjacent muscle, while the expression was
increased in the contraction band (Fig. 2A; 5 representa-
tive cases are shown). Semi-quantitative densitometric
analysis of the blots indicated that the levels of TGF-b1
and -b3 mRNA in the contraction band were increased
8.1 and 2.5-fold, respectively (Fig. 2B; mean of 23 cases;
P < 0.01), relative to adjacent muscle in the same
patients. The expression of TGF-b2 was not increased
(P > 0.05).
Immunohistochemical staining for TGF-b1, -b2, and -b3
We then performed immunostaining for TGF-b1, -b2,
and TGF-b3 to determine the immunolocalization and
level of expression in the contraction band and adjacent
muscle. Using immunohistochemical analysis, an
increased expression of TGF-b1 and -b3 was detected in
the fibroblasts (+++; arrow) and vascular endothelial
cells (+++; arrowhead) in the contraction band (Fig. 3A,
3C; Table 2). The expression of TGF-b1a n d- 3p r o t e i n
was weakly and sparsely detected in vascular endothelial
cells in adjacent muscle sections (+; Fig.3B, 3D; Table
2). The expression patterns of both TGF-b1a n dT G F -
b3 were similar. Compared to the adjacent muscle (+),
Table 1 Synthetic gene-specific primer sequences for collagen types I and III and for TGF-b1, -b2, -b3 and b-actin
Gene Primers Product Size
Collagen types I Forward GTCGAGGGCCAAGACGAAG 143 bp
Reverse CAGATCACGTCATCGCACAAC
Collagen type III Forward TGGTCCCCAAGGTGTCAAAG 117 bp
Reverse GGGGGTCCTGGGTTACCATTA
TGF-b1 Forward GGCCAGATCCTGTCCAAGC 201 bp
Reverse GTGGGTTTCCACCATTAGCAC
TGF-b2 Forward TGCCATCCCGCCCACTTTC 252 bp
Reverse GAGAGCCATTCGCCTTCTGC
TGF-b3 Forward CTGTGCGTGAGTGGCTGTTG 406 bp
Reverse GTGCTGTGGGTTGTGTCTGC
b-actin Forward ATCGTGCGTGACATTAAGGAGAAG 179 bp
Reverse AGGAAGGAAGGCTGGAAGAGTG
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detected in the contraction band from the same GMC
patient.
Expression of TGF-b1 and -b3 protein is up-regulated in
the contraction band
To further determine the level of protein expression of
TGF-b1, -b2, and -b3, we then examined these proteins
by western blot analysis. A strongly immunoreactive
band using TGF-b1a n d- b3 antibodies was detected in
all contraction band samples examined; however, the
immunoreactive band in adjacent muscle was very weak
(Fig.4A; 4 representative cases are shown). The protein
expression of TGF-b1a n d- b3 in the contraction band
were increased 11.2- and 4.5-fold, respectively (Fig. 4B;
mean of 23 cases; P < 0.01), relative to unaffected adja-
cent muscle in the same patients. Consistent with the
result of mRNA expression, TGF-b2w a sn o tu p - r e g u -
lated (P > 0.05).
Discussion
Although enormous work has been done to investigate
the mechanism of many fibrotic diseases, such as
keloids, atherosclerosis, liver cirrhosis, lung fibrosis, and
kidney fibrosis, the mechanism involved in this fibrotic
Figure 1 Histochemical analyses for muscle lesion and immunohistochemical analyses for collagen type I and type III. (A) Hematoxylin-
eosin, (B) Masson trichrome and (C) picrosirius staining of the boundary between the contraction band (CB) and unaffected adjacent muscle
(AM). Arrows indicate muscles that are undergoing fibrosis. (D) picrosirius staining of the boundary viewed under polarized light microscopy
(collagen type I is yellow and type III is green). (E, F, G, H) Immunohistochemical staining of contraction band (E, G) or unaffected adjacent
muscle (F, H) was carried out with antibodies against collagen type I (E, F) or collagen type III (G, H). Proteins specifically recognized by the
antibodies are stained red, whereas nuclei are counter-stained blue. Scale bars: 100 μm (A, B, C, D), 50 μm (E, F, G, H).
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study, we detected the expression and localization of
collagen types I and III, and TGF-bs in GMC patients
by immunohistochemistry, RT-PCR, and western blot
analysis.
Our first experiment demonstrated that collagen types
I and III were major components of the contraction
band and were remarkably elevated compared to unaf-
fected adjacent muscle. Several reports have documen-
ted increased synthesis of extracellular matrix (ECM),
including collagen type I, during development of fibrosis
in experimental and human diseases. However, in terms
of collagen type III, the status of synthesis is controver-
sial. Indeed, some reports have suggested that synthesis
is elevated and some have demonstrated that synthesis
is unchanged [20]. A possible explanation for this differ-
ence could be that cultured fibroblasts obtained from
fibrotic lesions have lost specific characteristics. Type III
collagen gene expression might be transiently activated
in specific stages of development of fibrosis, while those
Figure 2 (A) Expression of collagen types I, type III, TGF-b sa n db-actin mRNA in adjacent muscle and contraction band in 5 of the
GMC patients by RT-PCR. (B) Densitometry of mRNA levels of collagen types I, III and TGF-b s in contraction band and adjacent muscle (fold
change). The results are shown relative mRNA level of collagen types I, type III, and TGF-b s in contraction band compared with adjacent muscle
in 23 GMC patients.
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Adjacent Muscle
Collagen Type I Collagen Type III TGF-b1 TGF-b2 TGF-b3
Adjacent Muscle + -
Fibroblasts + - +
Endothelial cell + - +
Contraction Band +++ ++
Fibroblasts +++ + ++
Endothelial cell +++ + ++
Semi-quantitative scale: (-) = no staining; (+) = weak staining; (++) = moderate staining; and (+++) = strong staining.
Figure 3 Immunohistochemical analyses for TGF-b1, TGF-b2a n dT G F - b3 in contraction band (A, C, E, G) and unaffected adjacent
muscle (B, D, F, H). Staining was carried out with antibodies against TGF-b1 (A, B), TGF-b2 (C, D), TGF-b3 (E, F) or without first antibody
(control) (G, H). Proteins specifically recognized by the antibodies are stained red, whereas nuclei are counter-stained blue. Positive cells are
fibroblasts (arrowheads) and vascular endothelial cell (arrows). Scale bars: 50 μm (A-H).
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inactive in other stages, as supported by the work of
Zhang [21].
TGF-bs are pluripotent growth factors and are highly
conserved between species. There is 64%-85% amino
acid sequence homology between TGF-bs. These TGF-
bsi s o f o r m sb i n dt oc o m m o ns p e c i f i ct r a n s m e m b r a n e
receptors (TGF-b receptor types I and II) to target
genes via the SMAD family of signal transducing pro-
teins [22]. Previous studies have shown that TGF-bs
play pivotal roles in the development of fibrosis in var-
ious tissues and organs [15-19]. Their role on tran-
scriptional activation of collagen genes and post-
translational modification makes them potential candi-
dates to contribute in matrix remodeling during the
fibrosis. Thus, we believe that the formation of GMC
is due, at least in part, to an alteration of expression of
the TGF-b family. In our study, we found that the
mRNA expression of TGF-b1a n dT G F - b3i sr e m a r k -
ably increased in contraction band compared with the
expression in unaffected adjacent muscles. These
observations were enhanced using immunohistochem-
istry and western blot analysis. From the results of our
study, and taking into account the findings of previous
studies, it is suggested that up-regulation of TGF-b1
and TGF-b3i nt h ec o n t r a c t i o nb a n di nG M Cp a t i e n t s
contribute to muscle fibrosis. The results also suggest
that the process of fibrosis in GMC patients might be
a result of competition between the profibrotic func-
tion of TGF-b1 and the anti-fibrotic function of TGF-
b3. Further study would be done to investigate
whether TGF-b1-to-TGF-b3 ratio would influence pro-
gresses of fibrosis as some research reported [23].
However, in terms of TGF-b2, there was no evidence
i n d i c a t i n gad i f f e r e n c eb e t w e e nt h et w ok i n d so ft i s s u e s
at the two levels. Previous studies have emphasized that
TGF-b2 has a potential role in the formation of fibrosis,
but the time window is not clear [24]. From our findings
in the experiments herein, we hypothesize that TGF-b2i s
secreted only at the initial stage and might be an assistant
factor for TGF-b1 in fibrosis in gluteal muscle in vivo.
Curiously, in the survey of our post-operative patients,
most undergo another form of fibrosis (hypertrophic
scars in skin or keloids in the incision site) which is in
agreement with other reports [25,26]. These patients
seemingly have a tendency towards fibrosis in organs.
Whether there is a healing-associated gene variation in
these patients needs additional work for confirmation.
Figure 4 (A) Expression of TGF-b s and b-actin protein in adjacent muscle and contraction band in 5 of the GMC patients by Western
blot analysis. (B) Densitometry of protein levels of TGF-b s in contraction band and adjacent muscle (fold change). The results are shown
relative protein level of TGF-b s in contraction band compared with adjacent muscle in 23 GMC patients.
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The present study confirmed our hypothesis that GMC
is a fibrotic disease of gluteal muscle characterized by
accumulation of collagen types I and III, and up-regula-
tion of TGF-b1a n d- b3. All of these findings could be
important in understanding the molecular mechanism
of GMC and could provide specific sites for molecular
intervention for treatment or arrest of the progression
of this disease.
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